| Schedule of Fair Value Measurements on a Recurring Basis |
The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: | | | September 30, 2026 | | | | | Level 1 | | | Level 2 | | | Level 3 | | | Total | | | Assets: | | | | | | | | | | | | | | Marketable Securities (see note 3): | | | | | | | | | | | | | | DNA | | | 583 | | | | - | | | | - | | | | 583 | | | Nano | | | 10,801 | | | | - | | | | - | | | | 10,801 | | | Investments at fair value (see note 4): | | | | | | | | | | | | | | | | | | Ruby Capital | | | - | | | | - | | | | 449 | | | | 449 | | | Scilex Royalty Purchase Agreement | | | - | | | | - | | | | 1,749 | | | | 1,749 | | | Scilex Tranche A Note | | | - | | | | - | | | | 18,716 | | | | 18,716 | | | Scilex Tranche B Note | | | - | | | | - | | | | 4,591 | | | | 4,591 | | | Scilex Warrants Note B | | | - | | | | - | | | | 97 | | | | 97 | | | Lifeward’s A&R Warrants (see note 8) | | | - | | | | - | | | | 1,675 | | | | 1,675 | | | Lifeward’s A&R Note and Note Warrants (see note 8) | | | - | | | | - | | | | 7,857 | | | | 7,857 | | | Alpha Tau’s warrants | | | - | | | | - | | | | 36,626 | | | | 36,626 | | | Warren at Bay Loan | | | - | | | | - | | | | 2,703 | | | | 2,703 | | | 83 Wythe Loan | | | - | | | | - | | | | 2,341 | | | | 2,341 | | | Profit Sharing Loan Agreement | | | - | | | | - | | | | 3,338 | | | | 3,338 | | | Loan agreement measured in fair value (see note 7) | | | - | | | | - | | | | 37,883 | | | | 37,883 | | | Loan to an Equity Method Investee (see note 6) | | | - | | | | - | | | | 4 | | | | 4 | | | Investment in associates at fair value (see note 8): | | | | | | | | | | | | | | | | | | Alpha Tau’s shares | | | 215,739 | | | | - | | | | - | | | | 215,739 | | | Lifeward’s shares | | | 8,252 | | | | - | | | | - | | | | 8,252 | | | Lifeward’s A&R Pre-Funded Warrants | | | - | | | | 6,640 | | | | - | | | | 6,640 | | | | | $ | 235,375 | | | $ | 6,640 | | | $ | 118,029 | | | $ | 360,044 | | | | | December 31, 2025 | | | | | Level 1 | | | Level 2 | | | Level 3 | | | Total | | | Assets: | | | | | | | | | | | | | | Marketable Securities (see note 3): | | | | | | | | | | | | | | DNA | | | 540 | | | | - | | | | - | | | | 540 | | | Entera | | | 227 | | | | - | | | | - | | | | 227 | | | Pelthos | | | 4,650 | | | | - | | | | - | | | | 4,650 | | | Nano | | | 8,371 | | | | - | | | | - | | | | 8,371 | | | Investments at fair value (see note 4): | | | | | | | | | | | | | | | | | | Scilex Royalty Purchase Agreement | | | - | | | | - | | | | 2,209 | | | | 2,209 | | | Scilex Tranche A Note | | | - | | | | - | | | | 23,063 | | | | 23,063 | | | Scilex Warrants Note B | | | - | | | | - | | | | 850 | | | | 850 | | | Scilex Tranche B Note | | | - | | | | - | | | | 11,473 | | | | 11,473 | | | Loan agreement measured in fair value (see note 7) | | | - | | | | - | | | | 27,943 | | | | 27,943 | | | Investment in Alpha Tau’s warrants (see note 8) | | | - | | | | - | | | | 6,242 | | | | 6,242 | | | Profit Sharing Loan Agreement | | | - | | | | - | | | | 1,890 | | | | 1,890 | | | Investment in Alpha Tau’s shares (see note 8) | | | 71,623 | | | | - | | | | - | | | | 71,623 | | | Loan to an equity method investee (see note 6) | | | - | | | | - | | | | 553 | | | | 553 | | | Convertible note (see note 8) | | | - | | | | - | | | | 4,636 | | | | 4,636 | | | | | $ | 85,411 | | | $ | - | | | $ | 78,859 | | | $ | 164,270 | |
|